

1. A method of treating a patient afflicted with a neoplastic cancer, the method comprising oral administration of a pharmaceutical composition to the patient, the pharmaceutical composition consisting essentially of

- (a) a taxane;
- (b) a solvent capable of dissolving the taxane;
- (c) polyoxyethylated castor oil;
- (d) a diluent; and
- (e) optionally, a flavoring;

wherein the taxane has a solubility in ethanol at room temperature of at least 200 mg/ml.

2. The method of claim 1 wherein the composition contains a flavoring.

3. The method of claim 1 wherein the solvent capable of dissolving the taxane is ethanol.

4. The method of claim 1 wherein the diluent is water, saline, dextrose or an electrolyte solution.

5. The method of claim 1 wherein the solvent capable of dissolving the taxane is ethanol and the diluent is saline.

6. The method of claim 5 wherein the ethanol and polyoxyethylated castor oil are present in a volumetric ratio of about 1 to 1.

7. The method of claim 1 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 4 times less than that of paclitaxel.

8. The method of claim 1 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 7 times less than that of paclitaxel.

9. The method of claim 1 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 10 times less than that of paclitaxel.

10. The method of claim 1 wherein the taxane has a solubility in ethanol at room temperature of at least 500 mg/ml.

11. The method of claim 1 wherein the taxane has a solubility in ethanol at room temperature of at least 800 mg/ml.

12. The method of claim 10 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 4 times less than that of paclitaxel.

13. The method of claim 10 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 7 times less than that of paclitaxel.

14. The method of claim 10 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 10 times less than that of paclitaxel.

15. The method of claim 11 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 4 times less than that of paclitaxel.

16. The method of claim 11 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 7 times less than that of paclitaxel.

17. The method of claim 11 wherein the taxane has an ID_{50} value determined relative to the HCT116 cell line that is at least 10 times less than that of paclitaxel.